Humana Inc (HUM) Stock Price Today
Aura AI Summary
Key Stats
- $50.18BMarket Cap
- 1,368,425Volume
- HealthSector
- $433.5052W High
- $163.6752W Low
- 52 DaysTypical Hold Time
- $57.53BEnterprise Value
- 0.85%Div Yield
- 100% Sell | 0% BuyTrading Activity
Track Humana Inc (HUM) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Humana Inc has traded between a low of $163.67 and a high of $433.5, highlighting its annual price range. Buy and sell Humana Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Most Recent News
Cap expands onchain credit marketplace to finance film production without tokenizing assets
Cap, an onchain credit marketplace, is expanding into film and media financing by providing funding for the upcoming film Wake. This deal uses advances against anticipated film production tax credits, showing how Cap's underwriting model supports spe...
ANZ dental implants market to grow 5% CAGR, reaching $393M by 2033 driven by aging population and prosthetic demand
The Australia and New Zealand (ANZ) dental implants market, valued at $266 million in 2025, is projected to grow at a 5% CAGR to $393 million by 2033. Growth is driven by increasing demand for oral rehabilitation and prosthetic dentistry, especially ...
Good Life Meds must stop unproven health and personalization claims for compounded Tirzepatide+ products.
The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked ...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.